☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
EGFR Exon20 Insertion
Takeda's Exkivity (mobocertinib) Receives the US FDA's Approval as the First Oral Therapy for EGFR Exon20 Insertion+ NSCLC
September 16, 2021
Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC
May 20, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.